Trials / Not Yet Recruiting
Not Yet RecruitingNCT07227779
B-PaLMZ for TB Meningitis
A PHASE 2 NOVEL ANTIMICROBIAL COMBINATION THERAPY TO TREAT TUBERCULOUS MENINGITIS
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- Sponsor
- University of Minnesota · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This two-stage study will compare consented research participants with tuberculous meningitis receiving BPaLMZ to controls receiving SOC of rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E), known as RHZE.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BPaLMZ Regimen | bedaquiline, pretomanid, linezolid, moxifloxacin, and pyrazinamide |
Timeline
- Start date
- 2026-06-15
- Primary completion
- 2030-08-31
- Completion
- 2030-08-31
- First posted
- 2025-11-13
- Last updated
- 2026-04-14
Locations
2 sites across 2 countries: United States, Uganda
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07227779. Inclusion in this directory is not an endorsement.